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Previously we have shown that photodynamic therapy 
(PDT) of Lewis lung carcinoma (LLC) with HP - antiVEGF 
conjugate, in contrast to application of native hemato-
porphyrin, results in 60% slowdown of tumor growth that, 
in accordance with provisions of State Pharmacological 
Center of Ukraine, is considered to be a  significant anti-
tumor activity of the agent [1]. These results necessitated 
subsequent studies of antitumor and antimetastatic ac-
tivity in other tumor models. Thus, the purpose of present 
study was further investigation of anticancer action of 
HP-antiVEGF, in particular, the HP - antiVEGF effect on 
the growth of primary tumors and metastasis incidence 
on the model of LLC and its angiogenesis-dependent 
low-metastasis variant LLC/R9 (LLC/R9). Both tumors 
form metastasis in lungs after intramuscular or subcu-
taneous transplantation of tumors. 
First, we had to estimate, whether antitumor action 
of HP-antiVEGF applies to LLC/R9, that was obtained 
as a result of selective action of cisDDP in vivo. Se-
cond, we had to clarify how HP-antiVEGF acts at the 
lifespan of mice with LLC, and also we wish to compare 
the action of HP-antiVEGF with a known photosensi-
tizer — aminolevulinic acid (ALA). Third, we had to ex-
plore the action of HP-antiVEGF as  antimetastastatic 
agent on angiogenesis-dependent LLC/R9. 
MATERIALS AND METHODS 
Tumor models.The experiments were done on 
the 16–20 g mice of CC57 Bl/6 strain at the age of 
2 months bred in the vivarium of IEPOR NAS Ukraine.
Experimental procedures were approved by the Ethi-
cal Committee of IEPOR. Experimental tumor models 
in vivo were Lewis lung carcinoma strains — high and 
low metastatic variants (LLC and LLC/R9, respec-
tively). 
LLC/R9 — is a varient obtained from initial Lewis 
carcinoma strain after 9 consecutive courses of chemo-
therapy with cis-DDP [2], strain LLC was received from 
the National cell culture and tumor strain bank of IEPOR. 
Mice of CC57Bl line were inoculated into the foot pad 
with 0.3 х 106 cells either of LLC or of LLC/R9 in 0.1 ml of 
Hanks solution. Cells were obtained by routine method 
of cell disintegration with trypsin solution. Experiments 
were done on the animals with tumors of 0,5–0,7 cm 
diameter on the 21st day after inoculation. 
Experimental treatment. In experimental group 
HP - antiVEGF was applied for exploration of photody-
namic effect. Preparation was dissolved in the mixture 
of saline (0.9% NaCl) and DMSO in a 5 : 1 ratio. Dose 
per animal — 3 mg of conjugate in 0.1 ml of solution 
mixture. Conjugate was inoculated by intraperitoneal 
injection. Dose of hematoporphyrin in the conjugate 
was 0.04–0.05 mg. For comparison native hematopor-
phyrin or ALA (as additional control) were  introduced in 
saline solution by intramuscular injection and per os, re-
spectively, in the dose of 1 mcg/0.2 ml per animal. 24 h 
after conjugate or hematoporphyrin inoculation and 4 h 
after ALA treatment tumors were irradiated with laser 
radiation — initial capacity 25 mWatt, radiation dose — 
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50 watt-second/cm2, time of the procedure — 5 min. 
Other animal groups received either photosensitizer or 
laser irradiation alone.
Therapy assessments. Mice were observed du-
ring 7–40 days after PDT: life span, body mass, tumor 
size and mass, lymphoid organs mass, size an amount 
of lung metastases were estimated. Tumor growth 
kinetics was studied by calculation of the following 
parameters: dynamics of tumor volume alteration 
and percentage of growth inhibition. Measurement of 
tumor diameter was performed with caliper every two 
days, beginning from the day of the sensitizer introduc-
tion. Tumor volume was calculated by the formula: 
V = 4/3 × π × R3,
where R — tumor radius.
Tumor growth inhibition was calculated from the 
ratio of tumor volumes in control and experimental 
groups by the formula:
 Vk – VеTumor growth inhibition = ———— × 100%,
 Vk
where Vk — mean tumor volume in control group, Vе — 
mean tumor volume in experimental group.
Metastases in lungs were calculated by generally 
adopted method of Bouin fixative immersion on day 
30–50 after cells inoculation. Volume of metastatic 
lesions and the ratio of metastases in vascular and 
avascular (d ≤ 1,5 mm) phases were calculated [3].
Volume of a metastatic lesion was determined by 
the formula:
 N π × diV = Σ n × ———,
 i = 1 6
where di — diameter of metastases, ni — number of 
metastases with diameter di.
Statistics was calculated with generally adopted 
methods by Student’s t-criterion and coefficient of 
correlation.
RESULTS AND DISCUSSION
Experiments were performed on three groups of 
mice: 1st group (control) — mice, that received tumor 
LLC/R9 cells only; 2nd group — mice that on day 21 
after tumor cells transplantation, when the tumors 
achieved 0.5–0.7 cm in diameter, were injected with 
HP - antiVEGF; 3rd group — PDT of mice, whose tumors 
were treated by laser irradiation 24 h after photosen-
sitizer injection. Mice from all groups were sacrificed 
at the same time 7 days after laser irradiation in the 3rd 
group. Tumor mass in parallel with body and lymphoid 
organs mass were estimated. 
Results of PDT with conjugated photosensitiser are 
presented in Table 1. From the data presented in the 
table it is evident that, in spite of the substantial differ-
ence in tumor mass between control and PDT groups, 
statistically calculated difference is not significant. How-
ever, the presence of the animals — PDT respon ders in 
the groups of conjugate alone and PDT with conjugate 
is evident from the data obtained. For potential drugs 
with antitumor activity, one of the criteria in the assess-
ment of antitumor action is tumor growth inhibition, 
and for Lewis lung carcinoma the minimal percentage 
of the growth inhibition should be equal or higher than 
50% [1]. Under the conditions of our experiment in 
the group with conjugate this index is 70%. During this 
experiment the regimen of observation was adhered to 
those recommended by State Pharmacologic center of 
Ukraine — i. e. 7 days after final introduction of the drug 
(in our case, after performance of laser irradiation). 
Therefore new conjugated photosensitizer should be 
considered perspective for further approbation with 
prospective involvement into clinical practice. 
Assessment of absolute and relative lymphoid or-
gans mass ratio between a lymphoid organ mass and 
a total animal mass, estimated by comparison of organ 
indices in different groups, did not reveal  statistically 
significant differences. As Table 1 shows, dispersion 
(standard deviation) for each index inside each group 
was quite significant, therefore, we considered appro-
priate to carry out correlation analysis for such indices 
as spleen index, thymus index and tumor masses for 
each animal separately (Table 2).
Table 2. Ratio between relative masses of lymphoid organs and tumor 
masses during photodynamic therapy of LLC/R9 with HP-antiVEGF
Group
Correlation coefficient between:
Spleen index/
Thymus index
Spleen index/
tumor mass
Thymus index/
tumor mass
Control LLC/R9 –0.97 (–0.44)* 0.86 (–0.93)* –0.96 (0.06)*
HP-antiVEGF 0.10 (–0.51)* 0.01 (–0.02)* 0.42 (–0.18)*
PDT with HP-antiVEGF –0.38 (–0.37)* 0.78 (–0.06)* –0.63 (–0.3)*
Note: in parenthesis data from LLC original strain. 
Direct correlation was found between ratios of 
spleen index and tumor mass. Also, the strong inverse 
correlation was revealed between ratios of thymus in-
dex and tumor mass in untreated mice with tumors. As 
it is known, spleen is secondary immune organ, where 
sensitized lymphocytes migrate from lymph nodes. 
In spleen induction of T-dependent B-cell immune 
response, generation of B-lymphocytes, producing 
antibodies, and proliferation of CD8+ T-lymphocytes 
take place. Therefore, the direct correlation between 
spleen index and tumor mass may indicate the stimula-
tion of these functions by the developing tumor. 
It is known that two studied variants of Lewis carci-
noma are different in their influence on immune system. 
One of differences between LLC and LLC/R9 is different 
impact of tumor process on lymphoid organs mass. In 
tumor mice with LLC carcinoma the most pronounced 
involution of thymus in comparison with intact control 
animals takes place. Those effects have considerable 
Table 1. PDT with HP-antiVEGF  effect on the development of resistant strain LLC/R9, transplanted into the foot pads of mice C57Bl — 7 days after PDT
Group Body mass (g) Spleen mass (mg) Thymus mass (mg) Spleen index Thymus index Tumor mass (mg)
Control R9 (n = 7) 18.2 ± 2.25 164.67 ± 81.02 41 ± 8.88 8.9 ± 3.94 2.26 ± 0.51 54 ± 43.03
HP-antiVEGF (n = 6) 18.18 ± 2.4 104.16 ± 26.32 39.16 ± 7.33 5.9 ± 1.97 2.17 ± 0.45 49.7 ± 46.9
PDT with HP-antiVEGF (n = 6) 21.26 ± 3.08 145.16 ± 60.25 51.5 ± 12.29 6.77 ± 2.46 2.4 ± 0.34 16 ± 15.18
Inhibition — 70% 
p contr. > 0.05 
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input on tumor-induced suppression. The last is caused 
by decrease of T-lymphocytes number due to thymus 
atrophy, which means inhibition of antitumor reactions 
[4]. In mice with LLC/R9 involution of thymus also takes 
place, however, in less extent than in mice with LLC. In 
animals with LLC/R9 tumor the highest size of spleen and 
spleen index in comparison with intact mice was detect-
ed. Augmentation of the named indices may be the result 
of the activation of humoral responce of tumor bearing 
host. Tables 1 and 2 show that photodynamic therapy 
with conjugate somewhat normalizes thymus indices, in 
other words, inhibits involution of this organ, while there 
was no noticeable influence on splenomegaly.
Thus, high antitumor activity of the conjugate (inhibition of 
tumor growth by 68%) was also confirmed with LLC/R9.
The other experiments demonstrated that photo-
dynamic therapy with conjugated photosensitizer, in 
contrast to PDT with hematoporphyrin leads to more 
than 60 percent inhibition of tumor growth (Table 3). 
This index was obtained 7 days after the conducted 
therapy — the term officially defined for registration 
of antitumor activity of the investigated preparations. 
Further we studied whether the single application of 
conjugate could lead to longer survival of animals — up 
to complete recovery of tumor-bearing mice. It was also 
necessary to compare the effects of the conjugate with 
those of well-known photosensitizers — hematopor-
phyrin and ALA [5, 6].
The experiment included 4 groups of mice, bearing 
LLC: group 1 — treated with conjugate HP - antiVEGF; 
group 2  — treated with HP; group 3 — treated with ALA; 
untreated control with LLC.
The animals were observed for seven weeks after 
PDT — until death of the last mouse in control group. 
The Figure presents the dynamics of the survival in 
tumor bearing animals.
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Figure. Survival (%) of mice with LLC after photodynamic therapy 
with different sensitizers
As the presented data show, up to four week after 
photodynamic therapy the survival of animals remains 
at about the same level in all groups. Seven weeks after 
treatment (9 weeks after tumor inoculation) all mice 
in control group and hematoporphyrin group died. 
Survival in group with conjugated hematoporphyrin 
was 40%, and in ALA group — 26%.
Therefore, it may be concluded that the conjugate 
of hematoporphyrin with VEGF antibodies was more 
effective antitumor agent in comparison both with 
native hematoporphyrin and with other widely used 
photosensitizer — aminolevulinic acid.
The next step in the study of antitumor activity of 
the conjugate was elucidation of its potential to induce 
long or suspended antitumor action in case of single 
application of PDT, as well as affecting metastases 
formation. Also, aiming at perspective clinical applica-
tion we had to study regression/progression of tumor 
process in each separate mouse. 
Mice with LLC/R9 tumors were divided into three 
groups with 10–12 animals in each group. The vol-
ume of primary tumor was measured. The inhibition 
of tumor growth on day 21 after inoculation (date of 
therapy start, in Table - day 0), on the 7th, 14th, 21st and 
27th day (day of animals sacrificing) was calculated. 
The results of this study revealed that the conjugated 
preparation had pronounced antitumor activity towards 
LLC/R9 (Table 3).
Table 3. Dynamics of change of tumor volume in animals with 
transplanted LLC/R9 after photodynamic therapy
Day 
after 
PDT
Control Hematoporphyrin HP-antiVEGF
V of tumor, 
mm3
V of tumor, 
mm3
Percent 
of growth 
inhibition
V of tumor, 
mm3
Percent 
of growth 
inhibition
0** 60.38 ± 23.3 51.94 ± 23.2 — 34.71 ± 20.4 42%
7 181.68 ± 4.2 104.27 ± 77.6 43% 70.6 ± 10.1 61%
14 866.46 ± 373.6 503.75 ± 205.5 — 245.67 ± 42.6 72%
21 1637.18 ± 345 948.5 ± 649.3 — 153.0* ± 27.3 90%*
28*** 1970.0 ± 111.7 1136.02 ± 52.5 42% 402.36 ± 62.7 80%
*The marked indices statistically significant differ from analogous indices in 
control group. р < 0.05; **the day of laser treatment — 1 day after application 
of photosensitizer; ***term of sacrificing of animals.
In particular, it was shown that conjugate has not 
only immediate, but also long-term, suspended an-
titumor action. Thus, conjugated hematoporphyrin 
inhibits by 61% the growth of primary tumor by the 7th 
day after photodynamic therapy comparing to control 
and elicits the long-lasting therapeutic effect, as by 
day 21 after PDT with the conjugate the percent of 
tumor inhibition grew to 90% (р < 0.05).
The subsequent data (Table 4) show that conjugated 
hematoporphyrin decreases both general number 
of metastases in a group (2.5 times), and volume of 
metastases (4 times) due to domination as a rule of 
metastases in avascular phase (data not presented). 
Thus, the conjugate may suppress vascularization of 
metastases, and PDT with this photosensitizer gains the 
characteristics of antiangiogenic therapy [7].
Table 4. Influence of photodynamic therapy on growth and metastases 
of LLC/R9
Control Hemato-porphyrin
HP-
antiVEGF
Primary tumor volume, mm3 1970.0 ± 
1115.7
1136.02 ± 
852.5
402.36 ± 
223.7
Average number of metastases in lungs 10 ± 5.3 2.56 ± 2.9 1.72 ± 0.6
Average volume of metastases, mm3 8.66 ± 5.3 2.36 ± 2.7 0.96 ± 0.5
General number of metastases in lungs 50 23 19
General volume of metastases, mm3 43.3 21.21 10.45
Therefore, high antitumor activity of conjugated 
hematoporphyrin-antiVEGF (inhibition of growth 
of epidermoid Lewis carcinoma by 68%) was also 
confirmed for angiogenesis-dependent variant of 
Lewis carcinoma — LLC/R9. We observed that this 
therapeutic effect was sustained, as by the day 21 after 
PDT inhibition of tumor growth increased to 90%. The 
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conjugated hematoporphyrin decreased both general 
number of metastases in a group (2.5 times) and the 
volume of metastases (4 times).
The conjugate of hematoporphyrin with antibod-
ies to VEGF was more effective antitumor agent in 
respect of survival prolongation in animals with Lewis 
carcinoma in comparison with both native hemato-
porphyrin and other widely spread photosensitizer — 
aminolevulinic acid.
Taking into consideration substantial prevalence in 
clinical practice of drug-resistant tumors and angio-
genesis-dependent character of metastasis process, 
further study and application of photosensitizers, con-
jugated with antibodies to VEGF, may help to improve 
clinical outcomes. 
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ИЗУЧЕНИЕ ФОТОДИНАМИЧЕСКОЙ ЭФФЕКТИВНОСТИ 
КОНЪЮГАТА ГЕМАТОПОРФИРИНА С АНТИТЕЛАМИ К VEgF 
НА МыШАх С КАРЦИНОМОЙ ЛЕГКОГО ЛЬЮИС
Цель: исследование возможного противоопухолевого и антиметастатического действия гематопорфирина, конъюгированного 
с антителами к VEGF, по сравнению с исходным гематопорфирином при фотодинамической терапии высокометастатиче-
ской зависимой от ангиогенеза карциномы Льюис (LLC) и ее низкометастатического независимого от ангиогенеза вариан-
та — LLC/R9. Meтоды: мышам с LLC или с LLC/R9 проводили фотодинамическую терапию (ФДТ) с новым фотосенсиби-
лизатором — гематопорфирином, конъюгированным с антителами к VEGF, при сравнении с исходным гематопорфирином 
или аминолевулиновой кислотой. Учитывали размеры опухоли и развитие метастазов. Результаты: при ФДТ с конъюгатом 
отмечен выраженный противоопухолевый эффект — задержка роста опухоли на 60–63%, в то время как исходный гема-
топорфирин в выбранных условиях значимого эффекта не оказывал. Наибольшее действие конъюгат оказывал на рост и 
метастазирование варианта опухоли LLC/R9, характеризующегося резистентностью к химиопрепаратам. Задержку опухо-
левого роста — вплоть до полной регрессии — отмечали уже на 3-и сутки после ФДТ и в общем она составляла около 70% 
по сравнению с контролем. Подсчет количества метастазов показал, что общий объем метастазов снизился в 7 раз в группе 
с конъюгатом и в 3,5 раза в группе с гематопорфирином. Выводы: принимая во внимание значительное превалирование 
в клинической практике химиорезистентных опухолей, а также зависимого от ангиогенеза характер метастазирования, 
дальнейшее изучение и применение фотосенсибилизаторов, конъюгированных с антителами к  VEGF, может улучшить 
результаты лечения. 
Kлючевые слова: фотосенсибилизаторы, антитела к VEGF, фотодинамическая терапия, карцинома легкого Льюис.
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